Clinical Trials Logo

Clinical Trial Summary

The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced malignancies, including lymphoma. The primary objectives in the dose expansion phase are to assess preliminary anti-tumor activity of REGN3767 alone and in combination with cemiplimab (separately by cohort) as measured by objective response rate (ORR).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03005782
Study type Interventional
Source Regeneron Pharmaceuticals
Contact Clinical Trials Administrator
Phone 844-734-6643
Email [email protected]
Status Recruiting
Phase Phase 1
Start date November 7, 2016
Completion date September 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT03236857 - A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies Phase 1
Terminated NCT00329329 - Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies Phase 1
Completed NCT00316511 - Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma Phase 1
Completed NCT02521389 - Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143 Phase 1
Completed NCT01407380 - Study of PWT33597 Mesylate in Subjects With Advanced Malignancies Phase 1
Completed NCT01404728 - Longitudinal Evaluation Study of Vaginal Stenosis With and Without Pelvic Radiation Therapy N/A
Recruiting NCT03678883 - 9-ING-41 in Patients With Advanced Cancers Phase 1/Phase 2
Completed NCT02257476 - Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors Phase 1
Completed NCT00320827 - Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component) Phase 1